Ipamorelin

Selective GH secretagogue that pairs with CJC-1295 as the gold-standard gentle GH-pulse stack.

Overview

Ipamorelin is a selective growth hormone releasing peptide (GHRP) that stimulates pituitary GH release without the cortisol and prolactin side effects that complicate older GHRPs like GHRP-2 and GHRP-6. This clean profile is why it's paired with CJC-1295 (no DAC) as the most widely recommended GH secretagogue stack in the optimization community.

Used alone, ipamorelin produces modest IGF-1 elevation. Paired with CJC-1295 no-DAC, the combination synergistically amplifies natural GH pulses - a more physiologic approach than exogenous HGH.

Response is typically milder than tesamorelin but side-effect profile is cleaner. Good starting point for GH secretagogue protocols, especially for users who reacted poorly to more aggressive compounds.

Mechanism of Action

Ipamorelin binds the GHSR (growth hormone secretagogue receptor / ghrelin receptor) with high selectivity, triggering GH release from the pituitary. Unlike GHRP-2 and GHRP-6, it does not meaningfully activate ACTH, cortisol, or prolactin pathways - making it a cleaner tool for isolating the GH-axis effect.

Community Usage Patterns

200–300 mcg SC, 1–3× daily on an empty stomach. Most common pattern: AM fasted + before bed. Typically stacked with CJC-1295 (no DAC) 100–200 mcg at same time points. 12–16 week cycles with IGF-1 assessed at 6–8 weeks.

Education only - not medical advice. Any protocol change should involve your licensed provider.

Deep Dive

How ipamorelin produces a growth hormone pulse

Ipamorelin is a **synthetic pentapeptide** (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, molecular weight about 712 Da) that acts as an agonist at the **growth hormone secretagogue receptor (GHSR-1a)**, the same receptor the hormone ghrelin binds, on the anterior pituitary and hypothalamus. Engaging that receptor does two things at once. It directly signals somatotroph cells in the pituitary to release stored growth hormone, and it functionally reduces the influence of **somatostatin**, the hypothalamic signal that normally restrains GH output. Easing that restraint is a large part of why a growth hormone releasing peptide (GHRP) can generate a sharper GH pulse than a GHRH analog does on its own.

This mechanism is also the reason GHRPs are so often paired with a GHRH analog. GHRH agonists act on a separate receptor (GHRH-R) and mainly drive GH synthesis and release, while GHRP-class molecules like ipamorelin add somatostatin withdrawal and a distinct secretory signal. Because the two pathways are complementary rather than redundant, combining them tends to produce a **supra-additive** rather than merely additive GH response, a synergy characterized in the foundational GHRP work of Cyril Bowers across the 1980s and 1990s. The practical result is a taller but still-pulsatile GH spike rather than the flat, continuous elevation associated with long-acting agents.

The honest state of the human evidence

This is where expectations deserve careful calibration. **Ipamorelin has never been approved for any human indication, and the published human trial base is thin.** The compound (originally Novo Nordisk's NNC-26-0161) was introduced by Raun and colleagues in 1998 in the European Journal of Endocrinology, which established its defining feature: in rat and swine models it released GH with potency comparable to older GHRPs but without the meaningful ACTH, cortisol, or prolactin rise that complicated GHRP-2 and GHRP-6. That selectivity is genuine and well documented, but it was demonstrated largely in preclinical systems.

Direct human data is limited and mostly early pharmacology. Gobburu and colleagues (1999, Pharmaceutical Research) gave single intravenous doses to healthy male volunteers and modeled the pharmacokinetics and GH response, confirming a dose-dependent GH rise, but this was a small single-dose study, not an efficacy trial. The largest controlled human testing actually pursued a different goal entirely: **postoperative ileus**, the slowed gut motility that follows abdominal surgery. In a Phase 2 randomized, double-blind, placebo-controlled proof-of-concept trial (Beck et al., 2014, International Journal of Colorectal Disease), intravenous ipamorelin **did not meet its primary endpoint**, and the compound was not carried forward to approval for that use.

What does not exist is a body of randomized controlled trials testing ipamorelin for the outcomes people commonly associate with it, such as fat loss, lean-mass change, recovery, sleep, or anti-aging. Nearly all of those associations are **inference from GH-axis physiology plus anecdote**, not direct trial evidence for this specific molecule. That distinction is the single most important thing to hold onto when deciding what to expect and what to measure.

Which biomarkers are worth tracking, and why

A random serum GH level is close to uninformative here. GH is secreted in **pulses** and cleared quickly (circulating half-life on the order of 10 to 20 minutes), so a single draw mostly reflects where you happened to land in a pulse cycle. The field works around this by following downstream and adjacent markers instead:

- **IGF-1** is the integrated readout. The liver translates sustained GH signaling into IGF-1, which is far more stable across the day and is the most informative single marker of whether a GH secretagogue is producing a measurable effect. It is most meaningful when interpreted against **age- and sex-adjusted reference ranges** (often expressed as a z-score) rather than as a raw number. - **IGFBP-3** is the main circulating carrier protein for IGF-1 and tends to move with GH activity, so it helps confirm that a change in IGF-1 reflects genuine axis stimulation rather than noise. - **Fasting glucose and fasting insulin** are followed because GH is a **counter-regulatory hormone** that opposes insulin action in peripheral tissue. Sustained GH-axis stimulation can nudge fasting glucose and insulin upward, so these help catch any drift in insulin sensitivity early. - **HbA1c** extends that same question across a roughly three-month window and is a reasonable companion marker on longer timelines.

A common pattern in the literature and in documented practice is a baseline panel before starting and a follow-up several weeks later, which is why the ipamorelin profile lists IGF-1 among its primary tracked markers.

Protocol-design context, offered only as education

None of the following is a recommendation to obtain or use ipamorelin. It simply explains why documented protocols tend to be structured the way they are. Empty-stomach timing comes up repeatedly because **elevated blood glucose, circulating free fatty acids, and a recent meal all raise somatostatin tone and blunt the GH pulse**, so the peptide works against a headwind when given after food. The general preference for pulsatile, short-acting approaches over continuous long-acting GH exposure reflects a view that preserving the natural pulsatile rhythm is more physiologic and less likely to disturb feedback. Discussions of cycling and upper limits usually trace back to theoretical **receptor desensitization** and to the broader principle that pushing IGF-1 into supraphysiologic territory is where GH-related risk tends to concentrate. Every one of these is a question to work through with a licensed clinician, not a self-directed instruction.

Regulatory status and safety realities

Ipamorelin is **not an FDA-approved drug** and has no approved therapeutic indication. Its standing for pharmacy compounding under section 503A of the Federal Food, Drug, and Cosmetic Act has been the subject of ongoing FDA advisory-committee review and reclassification, and that standing has shifted more than once, so it is best understood as an **unsettled and evolving regulatory picture** rather than a settled clearance. A practical consequence is that much of what circulates is sold as **"research use only, not for human consumption,"** which means identity, purity, sterility, and dose accuracy are not verified by any regulator.

Effects that come up in tracking contexts include possible **increased appetite** (ipamorelin binds the ghrelin receptor, though it is generally reported as less appetite-stimulating than older GHRPs such as GHRP-6), water retention, headache, flushing or tingling, and injection-site reactions. The longer-term cautions are the ones that apply to any GH-axis stimulation: potential shifts in insulin sensitivity, fluid retention, and the reason IGF-1 is monitored rather than simply maximized. Anyone considering this compound should treat it as an unapproved research peptide and involve a licensed clinician in the decision. MyProtocolStack is a tracking and education tool, not a source of medical advice.

Biomarkers to Track

When running Ipamorelin, these are the biomarkers most commonly tracked to assess response and safety:

Blood Work Checklist

Before starting Ipamorelin, baseline the right panel. The Peptide Blood Work Checklist covers the full baseline panel, what to add for Ipamorelin's class, and when to retest.

Reconstitution Calculator

Free calculator for Ipamorelin reconstitution math - vial size, BAC water volume, and exact syringe units.

Side Effects & Monitoring

What Ipamorelin side effects are commonly reported, when they appear, the red flags worth a provider call, and the biomarkers that catch issues early.

Results & What to Track

What Ipamorelin results actually look like in the data - the markers to measure, when they tend to move, and how to tell a real result from placebo.

Related Reading

• Ipamorelin Vs Sermorelin →
• Ipamorelin Cjc 1295 Protocol →
• Igf 1 Blood Test Guide →

Related Peptides

Stacks That Include Ipamorelin

Ipamorelin Head-to-Head Comparisons

Conditions Ipamorelin is Commonly Researched For

Frequently Asked Questions

Log doses, upload your lab PDFs, and let StackAI read your panel in context of what you're actually running. Free to start.